This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them is off-label by definition. Some people compute it anyway. The reasoning is pharmacological — e.g., "I will split the difference between steps" — but it is reasoning from theory, not from evidence.
Written in the hope of being told what I have missed.
Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been studied clinically. One mg of semaglutide is not equivalent to one mg of something else in any meaningful sense.
I had written a reply contradicting post #31 and deleted it. Here is what survived.
The confident answers on Splitting a weekly dose and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
Confirming post #31 from a second method, which matters more than confirming it from a second person.
Adding the boring version of Splitting a weekly dose, because the interesting version keeps getting posted and the boring one is usually right.
Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.
Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The published trials used a calendar-based schedule. Tolerability-based escalation has no formal evidence base but is not uncommon in practice.
This follows post #35 rather than contradicting it.
A missed dose in a weekly schedule is not a trough to chase. With a week-long half-life you are perturbing a slowly moving average, and the labelling for licensed products in this class says take it if the next dose is far enough away and skip it otherwise.
Coming back to post #35, because the follow-up matters more than the original answer.
The question underneath Splitting a weekly dose is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.
Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.
Appreciated. The plain phrasing does more work here than a longer post would.
Post #35 and I disagree about the size of the effect, not about the direction.
The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them is off-label by definition. Some people compute it anyway. The reasoning is pharmacological — e.g., "I will split the difference between steps" — but it is reasoning from theory, not from evidence.
Happy to be the one who is wrong here if it settles the question.
Taking post #37 at face value and following it one step further.
Practical note on Splitting a weekly dose: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.
Coming back to post #40, because the follow-up matters more than the original answer.
Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been studied clinically. One mg of semaglutide is not equivalent to one mg of something else in any meaningful sense.
Noting that I have skin in this question and have tried to discount for it.
Holding a dose indefinitely: the trials did not study indefinite holding at a non-maximum dose. The trials escalated to a target and then held that. What happens if you stay at an intermediate dose for years is not formally studied and extrapolation is the best available reasoning.
Steady state means the plasma concentration is stable from dose to dose. That happens around 4 to 5 half-lives. Before that, the concentration is rising with each dose. Escalating before steady state means escalating on incomplete information about the dose you are on.
Post #44 answers the question as asked. The question underneath it is different.
Speaking only to Splitting a weekly dose as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the variance between people is larger than the effect.
I read post #42 twice before replying, because I had assumed the opposite.
Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by real-world reports. The dose does not seem to stop working, but the longest trials are not indefinitely long.
When a dose reduction is the correct response to a side effect: if a side effect is dose-dependent (nausea, constipation, injection discomfort), reducing the dose is a reasonable response. If the side effect is not dose-dependent (e.g., hypoglycemia with insulin), dose reduction does not address the issue.
The variance between people here is larger than the effect being discussed.
Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a weekly dosing schedule. Splitting it flattens the curve further but loses the convenience of once-weekly dosing. The trade-off is convenience versus a slightly flatter concentration curve.
One of those cases where knowing the mechanism does not help the decision.
Dose and effect are not linear across the studied range for every compound in this class. Assuming a doubled dose gives a doubled effect is the reasoning error behind most disappointment.
Saving this. It is the version I will quote when the question comes round again.
Everything in post #49 holds. The case it does not cover is the one I have.
The starting dose in most of these programmes is a tolerance step and produces little effect by design. Judging the compound at the starting dose is judging the wrong thing.
That holds for the case as described. Change the assumptions and it may not.
Nothing to add on the substance. Thank you for taking the question at face value.
Building on post #52 rather than restating it.
Going back down a step is not a failure and the trials allowed it. Several protocols permitted a return to the previous dose for tolerability and then a second attempt at the step.
Splitting a weekly dose is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.
Post #55 and I disagree about the size of the effect, not about the direction.
If you are stepping up mainly because the schedule says so rather than because the current dose has stopped doing what you wanted, that is worth noticing before rather than afterwards.
Taking post #57 at face value and following it one step further.
The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long half-life, four weeks approaches steady state and you can assess the dose fairly. That is an argument for not going faster. It is not an argument against going slower.
That is the version I use. It may not be the version that is correct.
Adding the measurement that post #57 says would settle it.
Holding at a dose that is working is a legitimate position and it is not what the trial protocols did. The protocols escalated to a target because they were measuring the target dose, not finding each person's minimum.